ParfumGigi@aol.com
4 février, 2008 22:08
FDA to Review J&J Psoriasis Drug
Associated Press 02.04.08, 8:06 AM ET
HORSHAM, Pa. -
Johnson & Johnson's subsidiary Centocor Inc. said Monday the Food and Drug Administration will review its application for experimental drug CNTO 1275 for the treatment of psoriasis, a skin disease.
Centocor is seeking approval for the late-stage drug, also known as ustekinumab, to treat adults with chronic moderate-to-severe plaque psoriasis, which results from the overproduction of skin cells and causes red, scaly plaques that itch and bleed.
Centocor discovered ustekinumab and holds exclusive marketing rights to the product in the United States. Janssen-Cilag International NV has exclusive marketing rights in countries outside of the United States.
